<DOC>
	<DOCNO>NCT02345928</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability single ascend dose CNTO 7160 administer intravenously ( IV ) healthy participant multiple dose administer IV participant asthma atopic dermatitis .</brief_summary>
	<brief_title>A Single Ascending Dose Study Healthy Participants Multiple Ascending Dose Study CNTO 7160 Participants With Asthma Participants With Atopic Dermatitis</brief_title>
	<detailed_description>This Phase 1 , randomize , placebo-controlled , multicenter study CNTO 7160 . The study consist Screening Period , In-patient period ( 6 day healthy participant , 11 day asthmatic participant atopic dermatitis participant ) outpatient period ( 105 day healthy participant , 110 day asthmatic atopic dermatitis participant ) . The total duration participation participant approximately 21 week healthy participant , 25 week asthmatic participant , atopic dermatitis participant . All eligible participant randomly assign receive active agent placebo . The study conduct 2 part . In Part 1 , single ascending dos CNTO 7160 placebo administer sequential cohort healthy participant IV infusion . In Part 2 , ascend multiple dos CNTO 7160 placebo administer IV infusion sequential cohort participant asthma atopic dermatitis . Blood sample collect assessment pharmacokinetic pharmacodynamics parameter part 1 2 parameter , along assessment safety clinical effect part 2 . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Part 1 ( Healthy Participants ) : Participant must body weight range 50 100 kilogram ( kg ) inclusive body mass index ( BMI ) 19 30 kilogram per meter square ( kg/m^2 ) inclusive Part 1 ( Healthy Participants ) : Participant must healthy basis physical examination , medical history , vital sign 12lead ECG perform screen Part 2 ( Asthma Participants ) : Participant must body weight range 50 125 kg inclusive BMI 19 32 kg/m^2 inclusive Part 2 ( Asthma Participants ) : Participant must physician documented diagnosis asthma least 12 month screen Part 2 ( Atopic Dermatitis Participants ) : Participant must body weight range 50 100 kg inclusive BMI 19 30 kg/m^2 inclusive Part 2 ( Atopic Dermatitis Participants ) : Participant physician document diagnosis atopic dermatitis least 12 month screen base UK refinement Rajka Hanifin criterion Part 1 ( Healthy Participants ) : Participant known malignancy history malignancy , exception basal cell carcinoma squamous cell carcinoma situ skin treat evidence recurrence within 6 month prior Screening Visit Part 1 ( Healthy Participants ) : Participant currently history clinically significant cardiovascular disease , include limited history angina myocardial infarction , congestive heart failure , symptomatic atherosclerotic vascular disease , arrhythmia . Part 2 ( Asthma Participants ) : Participant known malignancy history malignancy , exception basal cell carcinoma squamous cell carcinoma situ skin treat evidence recurrence within 6 month prior Screening Visit Part 2 ( Asthma Participants ) : Participant serious infection ( eg , sepsis , pneumonia pyelonephritis ) , hospitalize receive IV antibiotic serious infection 4 month prior Screening Visit Part 2 ( Atopic Dermatitis Participants ) : Participant known malignancy history malignancy , exception basal cell carcinoma squamous cell carcinoma situ skin treat evidence recurrence within 6 month prior Screening Visit . Part 2 ( Atopic Dermatitis Participants ) : Participant serious infection ( eg , sepsis , pneumonia pyelonephritis ) , hospitalize receive IV antibiotic serious infection 4 month prior Screening Visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
	<keyword>CNTO 7160</keyword>
	<keyword>Healthy</keyword>
	<keyword>Asthma</keyword>
	<keyword>Atopic Dermatitis</keyword>
</DOC>